Direct-to-Consumer Genetic Testing: Finding a Clear Path Forward.

Area of Science:

• Genetics
• Regulatory Science
• Bioethics

Background:

• The direct-to-consumer (DTC) genetic testing market operates within a sophisticated and evolving regulatory landscape.
• Numerous federal, state, and ethical barriers impact market entry and operation.
• Historical non-compliance by companies like 23andMe with regulatory bodies, such as the US Food and Drug Administration (FDA), initially posed significant challenges.

Purpose of the Study:

• To examine the regulatory compliance strategies within the DTC genetic testing market.
• To analyze the impact of regulatory relationships on company success.
• To identify ongoing challenges in consumer genetic data privacy and result interpretation.

Main Methods:

• Review of regulatory history and compliance actions of key DTC genetic testing companies.
• Analysis of existing federal and state regulations governing genetic information.
• Examination of ethical considerations surrounding the monetization of genetic data.

Main Results:

• Early disregard for FDA guidance by 23andMe nearly led to market failure, but a subsequent change in strategy resulted in regulatory clearances.
• The DTC genetic testing industry continues to navigate a complex and often perplexing regulatory framework.
• Ethical concerns persist regarding the monetization of deidentified genetic data, as genetic information is inherently identifiable and not fully protected by the Health Insurance Portability and Accountability Act (HIPAA).

Conclusions:

• A collaborative relationship with regulatory agencies is crucial for success in the DTC genetic testing market.
• Continued development of regulatory oversight is necessary to safeguard consumer health and privacy.
• Addressing the need for interpretation of genetic test results and ensuring robust data protection remain critical challenges.